Technical analysis of BioCardia, Inc. (BCDA): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions.
Price Performance
| 1 month | +28.15% |
| 3 months | +29.21% |
| Year-to-date | +0.00% |
| 1 year | -18.83% |
| 3 years | -92.57% |
| 5 years | -99.11% |
52-Week Range
| 52-week High | $2.05 |
| 52-week Low | $0.75 |
| Avg Volume (90d) | 2.3M |
Technical Indicators
| SMA 50 | $0.98 |
| SMA 200 | $1.13 |
| Beta | 0.55 |
| 30-day Volatility (annualised) | 56.6% |
| Price vs SMA 50 | +27.7% |
| Price vs SMA 200 | +10.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.40 | |
| 2025-11 | $1.45 | +3.6% |
| 2025-12 | $1.25 | -13.8% |
| 2026-01 | $1.23 | -1.6% |
| 2026-02 | $1.29 | +4.9% |
| 2026-03 | $1.21 | -6.2% |
| 2026-04 | $1.14 | -5.8% |
| 2026-05 | $0.93 | -18.4% |
| 2026-06 | $1.24 | +33.3% |
| 2026-07 | $0.82 | -33.5% |
| 2026-08 | $1.14 | +38.3% |
| 2026-09 | $1.25 | +9.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $1.25 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 10.78 |
| EV / EBITDA | -0.82 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.59 |
| Current Ratio | 1.12 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -74.97 |